Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 2/20 | 0.41 |
| ▸ | HTR1D | P28221 | 2/20 | 0.35 |
| ▸ | HTR1B | P28222 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | HTR2C | P28335 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6741150 | 0.85 | FYN (0.40) | FYNHTR1DHTR1BCYP3A4CYP2C8 | |
| SCHEMBL6738851 | 0.85 | FYN (0.40) | FYNHTR1DHTR1BCYP3A4CYP2C8 | |
| SCHEMBL6731272 | 0.81 | FYN (0.35) | FYNHTR1DHTR1B | |
| SCHEMBL6739255 | 0.81 | FYN (0.39) | FYNHTR1DHTR1BCYP3A4CYP2C8 | |
| SCHEMBL6740666 | 0.80 | FYN (0.38) | FYNHTR1DHTR1BCYP3A4CYP2C8 | |
| SCHEMBL6731491 | 0.79 | FYN (0.35) | FYN | |
| SCHEMBL6740421 | 0.77 | CYP3A4 (0.37) | FYNHTR1DHTR1BCYP3A4CYP2C8 | |
| SCHEMBL6737916 | 0.77 | CYP3A4 (0.37) | FYNHTR1DHTR1BCYP3A4CYP2C8 | |
| SCHEMBL6738272 | 0.77 | CYP3A4 (0.35) | FYNCYP3A4CYP2C8S1PR3CYP2D6 | |
| SCHEMBL6735224 | 0.77 | FYN (0.33) | FYNCYP3A4CYP2C8S1PR3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6682785-B2 | A FLUOROANTHRACENE COMPOUNDS; HEAT RESISTANCE, RADIATION RESISTANCE, PHOTOSTABILITY | CLARIANT FINANCE (BVI) LIMITED (VG) | 2004-01-27 | — | — | US | disclosed |
| US-20030118749-A1 | A fluoroanthracene compounds; heat resistance, radiation resistance, photostability | CLARIANT INTERNATIONAL LTD. | 2003-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030118749-A1 | A fluoroanthracene compounds; heat resistance, radiation resistance, photostability | HSF1, ABCC1, FLNA | FYN 2215/4885HTR1D 1756/4885HTR1B 1469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.